News | May 23, 2017

miRagen Therapeutics To Present New Clinical Trial Data For MRG-106, An Oligonucleotide Therapeutic Targeting microRNA-155, At The American Society Of Clinical Oncology Annual Meeting

New Phase 1 data will be released including safety, efficacy and pharmacokinetics after intravenous and subcutaneous administration in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL)

Boulder, CO - Miragen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced today that new interim results from its ongoing Phase 1 clinical study of MRG-106 will be presented on June 5, 2017 at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in Chicago, Illinois.

MRG-106 is an inhibitor of microRNA-155. In CTCL, as well as certain other blood cancers, microRNA-155 is present at abnormally high levels and plays a role in the proliferation of blood and lymph cells. miRagen believes therapeutic inhibition of microRNA-155 can reduce aberrant cell proliferation and tumor growth that is characteristic of certain types of cancer.

“We look forward to presenting updated data from our ongoing Phase 1 trial evaluating MRG-106 in patients suffering from MF, a serious and sometimes disfiguring form of CTCL, at this year’s ASCO Annual Meeting,” said miRagen President and Chief Executive Officer, William S. Marshall, Ph.D. “The study being presented is an example of our commitment to developing innovative product candidates to treat serious diseases for which there are few, if any, viable therapeutic options. We believe that the experience gained in developing MRG-106 for MF may also allow us to address other indications where microRNA-155 is implicated in disease.”

Poster Presentation Details
Abstract title: Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL)

  • Poster session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
  • Poster number: 326
  • Date: Monday, June 5, 2017, 8:00 a.m. - 11:30 a.m. CT
  • Location: Hall A

For additional information, please visit the ASCO website: www.asco.org

About miRagen Therapeutics, Inc.

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen’s two lead product candidates, MRG-106 and MRG-201, are currently in Phase 1 clinical trials. miRagen’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis. In addition to miRagen’s clinical programs, it is developing a pipeline of pre-clinical product candidates. The goal of miRagen’s translational medicine strategy is to progress rapidly to first in human studies once it has established the pharmacokinetics, pharmacodynamics and safety of the product candidate in pre-clinical studies. For more information, please visit www.miragenrx.com.

For information on clinical trials please visit www.clinicaltrials.gov.

SOURCE: miRagen Therapeutics, Inc.